Table Info

Table 1.

Clinical characteristics of patients

Data	All patients	Without polyposis and hypertrophy SM	With polyposis and hypertrophy SM	P-value
Patients, N (%)	93 (100%)	50 (53.8%)	43 (46.2%)	0.382
Age	13.0 [10.0; 16.0]	11.0 [9.0; 13.0]	16.0 [14.0; 17.0]	< 0.001
z-height	0.59 [–0.19; 1.68]	0.59 [0.03; 1.86]	0.56 [–0.26; 1.05]	0.258
zBMI	–0.03 [–0.81; 1.15]	–0.01 [–0.46; 1.3]	–0.54 [–1.1; 0.31]	0.023
zFVC	1.2 [0.4; 2.0]	1.4 [0.7; 2.2]	0.6 [–0.3; 1.9]	0.008
zFEV₁/FVC	–1.3 [–2.1; –0.6]	–1.4 [–2.1; –0.8]	–1.2 [–2.3; –0.04]	0.385
zFEV₁	0.2 [–0.9; 1.01]	0.5 [–0.5; 1.1]	–0.5 [–1.4; 0.4]	0.007
RPF (L/min)	40.0 [30.2; 49.8]	41.7 [33.3; 56.0]	38.3 [28.0; 45.7]	0.047
TNSS (points)	6.0 [4.0; 8.0]	5.0 [3.5; 7.5]	8.0 [5.0; 8.0]	0.012
SNOT-22 (points)	18.0 [12.0; 25.0]	16.0 [10.0; 21.0]	22.0 [15.0; 31.0]	0.001
Eosinophils (10⁹/L)	0.3 [0.2; 0.6]	0.4 [0.2; 0.7]	0.3 [0.1; 0.5]	0.378
Total IgЕ (ME/mL)	183.3 [80.2; 399.7]	178.4 [92.6; 378.8]	201.6 [80.2; 399.7]	0.811

Data are presented as Me [Q1; Q3], where Me is the median, [Q1; Q3] are the 1st and 3rd quartiles due to a distribution other than normal. SNOT-22: Sino-Nasal Outcome Test-22; SM: sinonasal mucosa; BMI: body mass index; FEV₁/FVC: forced expiratory volume in 1 s/forced vital capacity; RPF: renal plasma flow; TNSS: Total Nasal Symptom Score

Declarations

Author contributions

SVK: Conceptualization, Resources, Investigation, Methodology, Validation, Visualization, Writing—original draft, Writing—review & editing. TIE: Conceptualization, Investigation, Formal analysis, Supervision, Resources, Writing—original draft, Writing—review & editing. EIK and EAL: Resources, Investigation, Methodology. RNK: Data curation, Software. KVG: Resources, Data curation. DYO, NAG, and NIK: Writing—review & editing. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare no competing interests.

Ethical approval

The study was approved by the Ethical Committee of the Volga Region Research Medical University (protocol No13, dated 10.10.2016).

Consent to participate

All participants and all primary caregivers gave written informed consent.

Consent to publication

Not applicable.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author (Svetlana Viktorovna Krasilnikova, mashkovasv@mail.ru) upon request.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Vizuete JAC, Sastre J, Bernal ADC, Picado C, Moragón EM, García JMI, et al. Asthma, rhinitis, and nasal polyp multimorbidities. Arch Bronconeumol (Engl Ed). 2019;55:146–55. [DOI] [PubMed]

Global Strategy for Asthma Management and Prevention (2019 update) [Internet]. Global Initiative for Asthma; © 2019 [cited 2024 Dec 4]. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

Hossny E, Adachi Y, Anastasiou E, Badellino H, Custovic A, El-Owaidy R, et al. Pediatric asthma comorbidities: Global impact and unmet needs. World Allergy Organ J. 2024;17:100909. [DOI] [PubMed] [PMC]

Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53:1901046. [DOI] [PubMed]

Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–8. [DOI] [PubMed]

Eliseeva TI, Krasilnikova SV, Geppe NA, Babaev SY, Tush EV, Khaletskaya OV, et al. Effect of Nasal Obstructive Disorders on Sinonasal Symptoms in Children with Different Levels of Bronchial Asthma Control. Can Respir J. 2018;2018:4835823. [DOI] [PubMed] [PMC]

Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. [DOI] [PubMed]

Eruslankin NI, Vagina AA, Krasilnikova SV, Khramov AA, Bulgakova VA, Balabolkin II, et al. Hypertrophic and polypous changes in the sinonasal mucosa in children with atopic bronchial asthma and allergic rhinitis. Allergology and Immunology in Pediatrics. 2021;1:35–43. [DOI]

Castillo JA, Plaza V, Rodrigo G, Juliá B, Picado C, Fernández C, et al. Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma. J Allergy Clin Immunol Glob. 2023;2:100134. [DOI] [PubMed] [PMC]

10.

Foxman EF, Storer JA, Fitzgerald ME, Wasik BR, Hou L, Zhao H, et al. Temperature-dependent innate defense against the common cold virus limits viral replication at warm temperature in mouse airway cells. Proc Natl Acad Sci U S A. 2015;112:827–32. [DOI] [PubMed] [PMC]

11.

Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13:293–859. [DOI] [PubMed]

12.

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58:1–464. [DOI] [PubMed]

13.

Huang C, Chang P, Huang Y, Lee T, Huang C, Wu P. Clinical Characteristics of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps in Adolescents. J Asthma Allergy. 2023;16:1197–206. [DOI] [PubMed] [PMC]

14.

Caimmi D, Matti E, Pelizzo G, Marseglia A, Caimmi S, Labò E, et al. Nasal polyposis in children. J Biol Regul Homeost Agents. 2012;26:S77–83. [PubMed]

15.

Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149:1491–503. [DOI] [PubMed] [PMC]

16.

Chen F, Wen L, Qiao L, Shi Z, Xue T, Chen X, et al. Impact of Allergy and Eosinophils on the Morbidity of Chronic Rhinosinusitis with Nasal Polyps in Northwest China. Int Arch Allergy Immunol. 2019;179:209–14. [DOI] [PubMed]

17.

Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331–57. [DOI] [PubMed] [PMC]

18.

Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016;4:565–72. [DOI] [PubMed] [PMC]

19.

Meng J, Zhou P, Liu Y, Liu F, Yi X, Liu S, et al. The development of nasal polyp disease involves early nasal mucosal inflammation and remodelling. PLoS One. 2013;8:e82373. [DOI] [PubMed] [PMC]

20.

Perić A, Vojvodić D, Vukomanović-Đurđević B, Baletić N. Eosinophilic inflammation in allergic rhinitis and nasal polyposis. Arh Hig Rada Toksikol. 2011;62:341–8. [DOI] [PubMed]

21.

Tomassen P, Vandeplas G, Zele TV, Cardell L, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449–56.e4. [DOI] [PubMed]

22.

Cheng W, Zheng C, Tian J, Shi G. T helper cell population and eosinophilia in nasal polyps. J Investig Allergol Clin Immunol. 2007;17:297–301. [PubMed]

23.

Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. Chest. 2019;156:141–9. [DOI] [PubMed] [PMC]

24.

Colas L, Magnan A, Brouard S. Immunoglobulin E response in health and disease beyond allergic disorders. Allergy. 2022;77:1700–18. [DOI] [PubMed]

25.

Krasil’nikova SV, Eliseeva TI, Tush EV, Bol’shova EV, Kubysheva NI, Balabolkin II. Features of local inflammation of nasal mucosa in children with bronchial asthma. Russian Otorhinolaryngology. 2020;19:22–30. [DOI]

26.

Wang M, Bu X, Luan G, Lin L, Wang Y, Jin J, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy. 2020;10:26. [DOI] [PubMed] [PMC]

27.

Pawankar R, Hayashi M, Yamanishi S, Igarashi T. The paradigm of cytokine networks in allergic airway inflammation. Curr Opin Allergy Clin Immunol. 2015;15:41–8. [DOI] [PubMed]

28.

Lim HF, Nair P. Airway Inflammation and Inflammatory Biomarkers. Semin Respir Crit Care Med. 2018;39:56–63. [DOI] [PubMed]

29.

Xie X, Wang P, Jin M, Wang Y, Qi L, Wu C, et al. IL-1β-induced epithelial cell and fibroblast transdifferentiation promotes neutrophil recruitment in chronic rhinosinusitis with nasal polyps. Nat Commun. 2024;15:9101. [DOI] [PubMed] [PMC]

30.

Hu K, Lee F, Cheng Y, Huang H. Vascular endothelial growth factor and children featuring nasal polyps. Int J Pediatr Otorhinolaryngol. 2007;71:23–8. [DOI] [PubMed]

31.

Nemati S, Keihanian F, Saeidinia A, Bakhshaei M. Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment. Drug Des Devel Ther. 2019;13:3383–9. [DOI] [PubMed] [PMC]

32.

Perić A, Vojvodić D, Radulović V, Vukomanović-Đurđević B, Miljanović O. Correlation between cytokine levels in nasal fluid and eosinophil counts in nasal polyp tissue in asthmatic and non-asthmatic patients. Allergol Immunopathol (Madr). 2011;39:133–9. [DOI] [PubMed]

33.

Krasilnikova SV, Tush EV, Frolov PA, Ovsyannikov DY, Terentyeva AB, Kubysheva NI, et al. Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study). Sovrem Tekhnologii Med. 2021;12:37–45. [DOI] [PubMed] [PMC]

34.

Krasilnikova SV, Ovsyannikov DY, Eliseeva TI, Tush EV, Bolshova EV, Larin RA, et al. Thymic Stromal Lymphopoietin as a Predictor of Hypertrophic Changes in the Nasal Mucosa in Children with Atopic Bronchial Asthma and Allergic Rhinitis. Pediatria Journal named after GN Speransky. 2020;99:71–8. [DOI]

35.

Jiang L, Zeng Y, Huang Z, Tang Y, Zeng Q, Liu W, et al. Immunopathologic characteristics of Chinese pediatric patients with chronic rhinosinusitis. World Allergy Organ J. 2021;14:100616. [DOI] [PubMed] [PMC]

36.

Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147:29–36. [DOI] [PubMed]

37.

Corso ED, Bilò MB, Matucci A, Seccia V, Braido F, Gelardi M, et al. Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement. J Pers Med. 2022;12:846. [DOI] [PubMed] [PMC]

38.

Lorenzo GD, Drago A, Pellitteri ME, Candore G, Colombo A, Gervasi F, et al. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. Int Arch Allergy Immunol. 2001;125:164–75. [DOI] [PubMed]

39.

Savlevich EL, Kurbacheva OM, Egorov VI, Dyneva ME, Shilovskiy IP, Khaitov MR. Gene expression levels of cytokines in different phenotypes of CRSwNP. Vestn Otorinolaringol. 2019;84:42–7. [DOI] [PubMed]

40.

Sun D, Joo Y, Auo H, Kang J. Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2009;266:981–6. [DOI] [PubMed]

41.

Nabavi M, Arshi S, Bahrami A, Aryan Z, Bemanian MH, Esmaeilzadeh H, et al. Increased level of interleukin-13, but not interleukin-4 and interferon-γ in chronic rhinosinusitis with nasal polyps. Allergol Immunopathol (Madr). 2014;42:465–71. [DOI] [PubMed]

42.

Turner JH, Li P, Chandra RK. Mucus T helper 2 biomarkers predict chronic rhinosinusitis disease severity and prior surgical intervention. Int Forum Allergy Rhinol. 2018;8:1175–83. [DOI] [PubMed] [PMC]

43.

Aazami H, Seif F, Ghalehbaghi B, Mohebbi A, Ahmadi A, Babaheidarian P, et al. Levels of total IgA and IgA subclasses in the serum of chronic rhinosinusitis patients. Med J Islam Repub Iran. 2018;32:94. [DOI] [PubMed] [PMC]

44.

Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab. Expert Rev Clin Immunol. 2020;16:1115–25. [DOI] [PubMed]

45.

Guo C, Liu F, Wang D, Liu Z. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP. Curr Allergy Asthma Rep. 2023;23:703–13. [DOI] [PubMed]

46.

Hannikainen P, Kahn C, Toskala E. Allergic Rhinitis, Rhinosinusitis, and Asthma: Connections Across the Unified Airway. Otolaryngol Clin North Am. 2024;57:171–8. [DOI] [PubMed]

47.

Ambrosino P, Marcuccio G, Raffio G, Formisano R, Candia C, Manzo F, et al. Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model. Life (Basel). 2024;14:899. [DOI] [PubMed] [PMC]

48.

Mohamad S, Hamid SSA, Azlina A, Shukri NM. Association of IL-1 gene polymorphisms with chronic rhinosinusitis with and without nasal polyp. Asia Pac Allergy. 2019;9:e22. [DOI] [PubMed] [PMC]

49.

Carsuzaa F, Bequignon E, Dufour X, de Bonnecaze G, Lecron JC, Favot L. Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps. Int J Mol Sci. 2021;23:417. [DOI] [PubMed] [PMC]

50.

Vlaykov A, Miśkiewicz-Orczyk K. Effect of IL-4, IL-5, IL-13, and IgE on Nasal Congestion in Patients with Allergic Rhinitis. Open Access Macedonian Journal of Medical Sciences. 2022;10:2225–9. [DOI]

51.

Delshad AA, Nadoushan MJ, Davati A, Rostami A. Expression of Vascular Endothelial Growth Factor in Nasal Polyp and Chronic Rhinosinusitis. Iran J Pathol. 2016;11:231–7. [PubMed] [PMC]

52.

Shah SA, Kobayashi M. Pathogenesis of chronic rhinosinusitis with nasal polyp and a prominent T2 endotype. Heliyon. 2023;9:e19249. [DOI] [PubMed] [PMC]